AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis

AbbVie, Inc. ABBV announced that the FDA approved a second indication for its inflammatory drug, Skyrizi (risankizumab), to treat patients with active psoriatic arthritis.